AstraZeneca announces positive quarter results thanks to performances by Oncology division

Astra Zeneca group has announced today its third quarter financial results. The group led by Pascal Soriot lost one third of its EBIT ($1.3bn) as compared to Q3 2017, due to the sales decline caused by blockbuster Crestor’s patent expiration. However, investors were impressed by results from the oncology division, which is currently the main group’s asset, thanks to sales increasing by 47% (YTD), and by 55% in the Chinese market, the second pharmaceutical market in the world. AstraZeneca’s shares rose 2% (London) after the results were announced (London).

(Source: AstraZeneca)